# A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

> **NCT05902598** · PHASE3 · COMPLETED · sponsor: **Visirna Therapeutics HK Limited** · enrollment: 37 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Plozasiran
- **DRUG:** Placebon

## Key facts

- **NCT ID:** NCT05902598
- **Lead sponsor:** Visirna Therapeutics HK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-10
- **Primary completion:** 2024-11-26
- **Final completion:** 2026-01-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902598, "A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT05902598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*